Aldosterone modulates neural vasomotor response in hypertension: role of calcitonin gene-related peptide.
OBJECTIVE
We analyse the effect of aldosterone on vasomotor response induced by electrical field stimulation (EFS) in mesenteric arteries from Wistar Kyoto (WKY) and spontaneously hypertensive rats (SHR).


RESULTS
Aldosterone (0.001-1 microM) reduced vasoconstrictor response to EFS in a dose- and time-dependent manner only in SHR. Thus, the rest of experiments were performed only in SHR. Aldosterone did not affect either noradrenaline response or release. Effect of aldosterone (1 microM) on EFS response was not affected by NG-nitro-arginine-methyl esther (100 microM), and was abolished by capsaicin (0.5 microM) and the calcitonin gene-related peptide antagonist (CGRP 8-37, 0.5 microM). Calcitonin gene-related peptide (0.1 nM-0.1 microM) induced a concentration-dependent relaxation, which was enhanced by aldosterone (1 microM). Incubation with either spironolactone (1 microM), glibenclamide (10 microM), RU 486 10 microM, ODQ (10 microM) or cycloheximide (10 microM) significantly reduced the enhancement of CGRP-relaxation produced by aldosterone, while remained unmodified by SQ 22,536.


CONCLUSIONS
Aldosterone decreases the vasoconstrictor response to EFS in mesenteric arteries from SHR but not from WKY. This effect is mediated by an increased response to the sensory neurotransmitter CGRP, substantially, through glucocorticoid receptors activation. Furthermore, this effect is mediated by an increase of cGMP synthesis and ATP-dependent potassium channel activation.
Balfagón
Gloria
G
Departamento de Fisiología, Facultad de Medicina, Universidad Autónoma de Madrid, C/Arzobispo Morcillo, 4, 28029, Spain. gloria.balfagon@uam.es
Márquez-Rodas
Iván
I
Alvarez
Yolanda
Y
Alonso
María Jesús
MJ
Cachofeiro
Victoria
V
Salaices
Mercedes
M
Lahera
Vicente
V
D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000378:metabolism; D000450:Aldosterone / Q000494:pharmacology*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D015740:Calcitonin Gene-Related Peptide / Q000502:physiology*; D002211:Capsaicin / Q000494:pharmacology; D006152:Cyclic GMP / Q000378:metabolism; D004558:Electric Stimulation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005905:Glyburide / Q000494:pharmacology; D006973:Hypertension / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008638:Mesenteric Arteries / Q000187:drug effects / Q000294:innervation; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009474:Neurons / Q000502:physiology*; D009638:Norepinephrine / Q000378:metabolism; D015221:Potassium Channels / Q000378:metabolism; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D011965:Receptors, Glucocorticoid / Q000378:metabolism; D013148:Spironolactone / Q000494:pharmacology; D014661:Vasoconstriction / Q000502:physiology; D014666:Vasomotor System / Q000502:physiology*
D000889:Anti-Arrhythmia Agents; D004791:Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D015221:Potassium Channels; D011965:Receptors, Glucocorticoid; C017759:9-(tetrahydro-2-furyl)-adenine; D013148:Spironolactone; D000450:Aldosterone; D000255:Adenosine Triphosphate; D006152:Cyclic GMP; D000225:Adenine; D015740:Calcitonin Gene-Related Peptide; D002211:Capsaicin; D005905:Glyburide; D019331:NG-Nitroarginine Methyl Ester; D009638:Norepinephrine